Lumos Pharma has been granted a patent for a compressed tablet containing ibutamoren to treat growth hormone deficiency in pediatric patients. The tablet includes specific ingredients and characteristics, such as a diameter of less than 4mm and a hardness of 2.5-6 Kp. GlobalData’s report on Lumos Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lumos Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Lumos Pharma's grant share as of May 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.